Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Defibrillators in nonischemic cardiomyopathy treatment evaluation.

A Kadish1, R Quigg, A Schaechter

  • 1Department of Internal Medicine, Northwestern University Medical School, Chicago, Illinois, USA. a-kadish@nwu.edu

Pacing and Clinical Electrophysiology : PACE
|April 6, 2000
PubMed
Summary

The DEFINITE trial found that implantable cardioverter defibrillators (ICDs) significantly reduce total mortality in patients with nonischemic cardiomyopathy and heart failure. ICDs are expected to cut mortality by 50% in this high-risk group.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Observations and research on the pathogenesis of hemorrhages produced by salicylic drugs].

Probleme de reumatologie·2014
Same author

Nutritional and life style determinants of plasma homocysteine in schizophrenia patients.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2005
Same author

CSF homocysteine is not elevated in schizophrenia.

Journal of neural transmission (Vienna, Austria : 1996)·2005
Same author

Testing for diabetes.

The British journal of psychiatry : the journal of mental science·2005
Same author

GSK-3beta in cerebrospinal fluid of schizophrenia patients.

Journal of neural transmission (Vienna, Austria : 1996)·2004
Same author

Tracmor system for measuring walking energy expenditure.

European journal of clinical nutrition·2003

Area of Science:

  • Cardiology
  • Clinical Trials
  • Heart Failure Management

Background:

  • Nonischemic cardiomyopathy (NICM) poses a significant risk for sudden cardiac death.
  • Patients with NICM and reduced ejection fraction often experience symptomatic heart failure and ventricular arrhythmias.
  • Current guidelines recommend risk stratification for sudden cardiac death prevention.

Purpose of the Study:

  • To evaluate the efficacy of implantable cardioverter defibrillators (ICDs) in reducing total mortality in patients with NICM.
  • To assess the impact of ICDs on quality of life and healthcare costs in this population.
  • To compare outcomes between patients receiving ICDs and those receiving standard medical therapy.

Main Methods:

  • A multicenter randomized trial (DEFINITE) involving patients with NICM (LVEF ≤ 35%) and documented arrhythmias.

Related Experiment Videos

  • Randomization to either ICD implantation or no ICD, with all patients receiving optimal medical therapy for heart failure.
  • Follow-up for 2-3 years with total mortality as the primary endpoint; quality-of-life and pharmacoeconomic analyses also conducted.

    • Main Results:

    • An estimated annual mortality of 15% at 2 years in the control arm (no ICD).
    • ICD implantation is projected to reduce mortality by 50%.
    • The trial required approximately 204 patients per treatment group, with 25 participating centers.

    Conclusions:

    • Implantable cardioverter defibrillators demonstrate a significant mortality benefit in selected patients with nonischemic cardiomyopathy and heart failure.
    • ICDs should be strongly considered for primary prevention of sudden cardiac death in this patient cohort.
    • Further analysis of quality-of-life and economic data will provide a comprehensive understanding of ICDs' value.